Ignite Creation Date:
2024-05-05 @ 5:16 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00422786
Status:
COMPLETED
Last Update Posted:
2008-07-15
First Post:
2007-01-12
Brief Title:
Phase II Study of CAP-232 in Patients With Refractory Metastatic Renal Cell Carcinoma
Sponsor:
Thallion Pharmaceuticals
Organization:
Thallion Pharmaceuticals
Organization Data
Organization:
Thallion Pharmaceuticals
Class:
INDUSTRY
Study ID:
CTP_CAP001
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Thallion Pharmaceuticals
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
None
Responsible Party Affiliation:
None
Old Name:
Didier Reymond MD Vice-President Medical and Clinical Affairs
Old Organization:
Thallion Pharmaceuticals Inc